Is There A Benefit of Restaging Transurethral Resection of Bladder Tumor Prior to Radical Cystectomy With or Without Neoadjuvant Chemotherapy?

Overview

Journal Bladder Cancer

Publisher IOS Press

Date 2024 Jul 12

PMID 38994480

Authors

Justin P Mehr

Jenna N Bates

Seth P Lerner

Affiliations

Soon will be listed here.

Abstract

Background: One of the best predictors of positive outcomes in bladder cancer (BC) is pT0 following radical cystectomy (RC). Discordance between clinical and pathologic staging affects decision-making in patients with clinical absence of disease (cT0).

Objectives: We sought to determine whether a restaging transurethral resection of bladder tumor (re-TURBT) improves clinical staging accuracy relative to pathologic stage RC in patients treated with neoadjuvant chemotherapy (NAC) versus those who did not receive NAC.

Methods: We queried our prospectively maintained IRB approved institutional database to identify 129 patients who underwent RC from 2013 to 2019 with a re-TURBT prior to RC. 53 patients were treated with NAC between their initial and re-TURBT and 76 patients were not treated with NAC.

Results: The overall upstaging rate from re-TURBT to RC was 34.9%. There was no significant difference in the upstaging rate between the NAC and no-NAC groups - 31.0% vs. 37.0%, respectively. In patients who were cT0 on re-TURBT, the NAC group did not show a significantly greater rate of pathologic clinical CR (pT0) than the no NAC group - 38.5% vs. 37.5%, respectively. Re-TURBT with staging < rT2 as a predictor for absence of MIBC on pathologic staging (<ypT2) did not show a significant difference between the NAC and no NAC group, with a negative predictive value (NPV) of 69.0% and 66.7%, respectively.

Conclusions: Re-TURBT after NAC does not show statistically significant improvement in staging accuracy relative to pathologic stage at RC compared to re-TURBT in patients not treated with NAC.

Citing Articles

Comparison between different neoadjuvant chemotherapy regimens and local therapy alone for bladder cancer: a systematic review and network meta-analysis of oncologic outcomes.

Aydh A, Sari Motlagh R, Alamri A, Yanagisawa T, Ayed A, Rajwa P World J Urol. 2023; 41(8):2185-2194.

PMID: 37347252 PMC: 10415490. DOI: 10.1007/s00345-023-04478-w.

References

Kukreja J, Porten S, Golla V, Ho P, Noguera-Gonzalez G, Navai N . Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Eur Urol Focus. 2017; 4(5):720-724. DOI: 10.1016/j.euf.2016.12.005. View

Yap S, Pugashetti N, Chandrasekar T, DallEra M, Evans C, Lara P . The Promise and Disappointment of Neoadjuvant Chemotherapy and Transurethral Resection for Muscle Invasive Bladder Cancer: Updated Results and Long-Term Followup. Urol Pract. 2023; 5(4):305-310. DOI: 10.1016/j.urpr.2017.07.001. View

Luo C, Huang B, Wu Y, Chen J, Chen L . Use of Vesical Imaging-Reporting and Data System (VI-RADS) for detecting the muscle invasion of bladder cancer: a diagnostic meta-analysis. Eur Radiol. 2020; 30(8):4606-4614. DOI: 10.1007/s00330-020-06802-z. View

Kassouf W, Spiess P, Brown G, Munsell M, Grossman H, Siefker-Radtke A . P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol. 2007; 52(3):769-74. PMC: 2691552. DOI: 10.1016/j.eururo.2007.03.086. View

Turker P, Bostrom P, Wroclawski M, Van Rhijn B, Kortekangas H, Kuk C . Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. BJU Int. 2012; 110(6):804-11. DOI: 10.1111/j.1464-410X.2012.10939.x. View

Tilki D, Svatek R, Novara G, Seitz M, Godoy G, Karakiewicz P . Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. J Urol. 2010; 184(3):888-94. DOI: 10.1016/j.juro.2010.04.081. View

Necchi A, Bandini M, Calareso G, Raggi D, Pederzoli F, Fare E . Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol. 2019; 77(5):636-643. DOI: 10.1016/j.eururo.2019.12.016. View

Sternberg C, Pansadoro V, Calabro F, Schnetzer S, Giannarelli D, Emiliozzi P . Can patient selection for bladder preservation be based on response to chemotherapy?. Cancer. 2003; 97(7):1644-52. DOI: 10.1002/cncr.11232. View

DeVere White R, Lara Jr P, Goldman B, Tangen C, Smith D, Wood Jr D . A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol. 2009; 181(6):2476-80. PMC: 2769926. DOI: 10.1016/j.juro.2009.01.115. View

10.

Tyson 2nd M, Barocas D . Quality of Life After Radical Cystectomy. Urol Clin North Am. 2018; 45(2):249-256. DOI: 10.1016/j.ucl.2017.12.008. View

11.

Robins D, Matulay J, Lipsky M, Meyer A, Ghandour R, Decastro G . Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy. Urology. 2017; 111:116-121. DOI: 10.1016/j.urology.2017.09.003. View

12.

Wang H, Luo C, Zhang F, Guan J, Li S, Yao H . Multiparametric MRI for Bladder Cancer: Validation of VI-RADS for the Detection of Detrusor Muscle Invasion. Radiology. 2019; 291(3):668-674. DOI: 10.1148/radiol.2019182506. View

13.

Bayraktar Z, Gurbuz G, Tasci A, Sevin G . Staging error in the bladder tumor: the correlation between stage of TUR and cystectomy. Int Urol Nephrol. 2002; 33(4):627-9. DOI: 10.1023/a:1020553812554. View

14.

Ficarra V, Dalpiaz O, Alrabi N, Novara G, Galfano A, Artibani W . Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int. 2005; 95(6):786-90. DOI: 10.1111/j.1464-410X.2005.05401.x. View

15.

Chang E, Apolo A, Bangs R, Chisolm S, Duddalwar V, Efstathiou J . Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop. Nat Rev Urol. 2021; 19(1):37-46. DOI: 10.1038/s41585-021-00505-w. View

16.

Hamid A, Ridwan F, Parikesit D, Widia F, Arif Mochtar C, Umbas R . Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients. BMC Urol. 2020; 20(1):158. PMC: 7557048. DOI: 10.1186/s12894-020-00733-z. View

17.

Kim S . Validation of vesical imaging reporting and data system for assessing muscle invasion in bladder tumor. Abdom Radiol (NY). 2019; 45(2):491-498. DOI: 10.1007/s00261-019-02190-1. View

18.

Panebianco V, Narumi Y, Altun E, Bochner B, Efstathiou J, Hafeez S . Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol. 2018; 74(3):294-306. PMC: 6690492. DOI: 10.1016/j.eururo.2018.04.029. View

19.

Saginala K, Barsouk A, Aluru J, Rawla P, Padala S, Barsouk A . Epidemiology of Bladder Cancer. Med Sci (Basel). 2020; 8(1). PMC: 7151633. DOI: 10.3390/medsci8010015. View

20.

Becker R, Meyer A, Brant A, Reese A, Biles M, Harris K . Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. 2020; 79(3):364-371. DOI: 10.1016/j.eururo.2020.07.016. View